OBJECTIVE To evaluate the psychometric properties of two health status measures for adults with growth hormone deficiency (GHD): Nottingham Health Profile (NHP) and Short-Form Health Survey (SF-36). DESIGN (1) A cross-sectional survey of adults with treated or untreated GHD, to assess reliability and validity of the questionnaires. (2) A randomised, placebocontrolled study of 3 months' GH withdrawal from GH-treated adults, to assess the questionnaires' sensitivity to change. PATIENTS (1) Cross-sectional survey of 157 patients with severe GHD (peak GH < 10mU/L on provocative testing), mean age 48.9 (range 23-70), who had either received GH-replacement therapy for at least 6 months immediately prior to the study, or had not received GH treatment in the previous 6 months. (2) GH treatment was withdrawn from 12 of 21 GH-treated adults, all with severe GHD (peak GH < 7.7 mU/L on provocative testing), mean age 44.9 (range 25-68). MEASUREMENTS The NHP and SF-36 were used once in the cross-sectional survey, but twice in the GH-withdrawal study, at baseline and end-point (after 3 months). RESULTS (1) Cross-sectional survey. Both questionnaires had high internal consistency reliability with subscale Cronbach's alphas of > 0.73 (NHP) and > 0.78 (SF-36). Calculation of a NHP Total score, occasionally reported in the literature, was shown to be inadvisable. Overall, patients with GHD were found to have significantly worse perceived functioning than the UK general population in SF-36 subscales of General Health, Pain, Social Functioning, Role-Emotional, Role-Physical, and Vitality. Whilst neither questionnaire found significant differences between GHtreated and non-GH-treated patients, there were correlations with duration of GH treatment (p < 0.01) for GH-treated patients, in SF-36 Mental Health [r = 0.29, N = 87] and SF-36 Vitality [r = 0.33, N = 88], indicating improvement with increasing treatment duration. The SF-36 was also more sensitive than the NHP to sex differences: men had significantly better health status compared with women (p < 0.05) in all SF-36 subscales but Mental Health, but only in one NHP subscale (Physical Mobility). (2) GH-withdrawal study. Significant between-group differences in change were found in SF-36 General Health [t(17) = 2.76, p = 0.013, 2-tailed] and SF-36 Mental Health [t(17) = 2.41, p = 0.027, 2-tailed]: patients withdrawn from GH reported reduced general health and mental health at end-point. The NHP found no significant change. CONCLUSIONS The SF-36 is a better measure than the NHP of health status of people with GHD, owing to its greater discriminatory power with ability to detect lesser degrees of disability. It also has superior sensitivity to some sub-group differences and superior sensitivity to change than the NHP. The SF-36 is highly acceptable to respondents, and has very good internal consistency reliability. The SF-36 is recommended to measure the health status of adults with GHD.
Introduction
The physical symptoms of adult GHD include abnormal body composition with reduced lean body mass and increased central adiposity; reduced muscle strength and exercise performance (Carroll et al. 1998) . However, psychological symptoms may be as important as physiological (Powrie et al. 1995) and it has been recommended that psychological variables should be considered when assessing patients for treatment (Bengtsson et al. 2000) . Psychological symptoms reported by adults with untreated GHD include low energy, tiredness, sleepiness, poor concentration, poor memory, irritability (Hunt et al. 1993) , anxiety, depression and mood swings (Wallymahmed et al. 1996) .
Health status has been one of the key psychological outcomes in adult GHD research and the NHP (Hunt et al. 1985 ) the most frequently used health status questionnaire with this patient group. The NHP has 6 subscales to measure Emotional Reactions, Energy, Pain, Physical Mobility, Sleep and Social Isolation. After 6 months' GH treatment in placebo-controlled studies improvements have been found in Energy (McGauley et al. 1990; Mardh et al. 1994; Carroll et al. 1997; Wallymahmed et al. 1997) ; Emotional Reactions (Carroll et al. 1997) ; Physical Mobility and Social Isolation (Attanasio et al. 1997; Carroll et al. 1997) . One study only obtained significant improvement in Emotional Reactions and Energy when patients with floor baseline scores 1 were excluded from analysis (Burman et al. 1995) . Others only found improvements in some NHP variables in the open label stages of the trial after 12+ months' GH treatment (Cuneo et al. 1998; Mardh et al. 1994) , or after 20-50 months (Wiren et al. 1998) . Some studies found no significant effects using the NHP (Whitehead et al. 1992; Baum et al. 1998 ). Thus energy has generally been found to improve when patients with GHD are given GH replacement therapy, but results for other aspects of health status have not always been consistent. The SF-36, a more recent measure of health status (Ware & Sherbourne 1992) , has 8 subscales to measure Bodily Pain, General Health, Mental Health, Physical Functioning, Role-Emotional, Role-Physical, Social Functioning and Vitality. It has been used less frequently than the NHP in research into adult GHD, generally in comparison studies.
Both the NHP and SF-36 measure how people feel about their health, but they have often been inappropriately referred to as measures of quality of life (QoL) in the research literature, where the terms "health status" and "quality of life" are frequently misused as if interchangeable (Bradley 2001; Smith et al. 1999) . Even if people feel that their health is poor, they may or may not also feel that their QoL is impaired, and vice versa. Treatments that improve health may conversely damage QoL, and may lead to poor adherence to therapy. "When a health-status measure is used to assess quality of life, the conclusions can be misleading" (Bradley 2001 ).
GH replacement therapy in adult GHD is not the norm in the UK, as there is controversy about whether the benefits outweigh the high financial costs and a treatment regimen requiring daily injections. Measures of psychological outcomes are required in addition to clinical outcomes to assess the effects of GH treatment. The frequently used NHP does not appear to have been previously validated psychometrically for use in adult GHD, and the opportunity was taken in the two studies described below to validate not only the NHP, but to compare its properties with those of the SF-36, which has been shown to be more sensitive than the NHP in the general population (Brazier et al. 1992) . The first study was a cross-sectional survey of 157 adults with severe GHD, both GH-treated and non-GH-treated, to investigate reliability, factor structure and construct validity of the questionnaires. Sensitivity to change was investigated in a randomised placebo-controlled study of 3 months' withdrawal of GH treatment from 12 of 21 GH-treated adults, where 9 continued with GH. The Guy's and St Thomas' Hospital Trust Ethics Committee gave approval for both studies.
The questionnaires

NHP
The NHP has 38 dichotomous negatively-worded items. 'No' responses (indicating good functioning) score zero, 'yes' responses can be weighted as described in the manual (Hunt & McKenna 1989) . Subscale scores range from 0 to 100, (lower scores indicating better health status).
SF-36
The 36-item SF-36 has 8 subscales with Likert scales of 2 to 6 response options and an additional item on perceived change in health over the previous year. SF-36 subscale scores range from 0 to100, (higher scores indicating better functioning). The UK version was used in the present studies. It was found to have high reliability with a UK general population (Brazier et al. 1992) , and was able to detect low levels of ill health in people who had scored 0 (indicating good health) on the NHP.
Both questionnaires have been used in the endocrine field. For example in hormone replacement therapy (Kenny et al. 2002; Ryan & Rosner 2001) , diabetes (Anderson et al. 1997; Benbow et al. 1998) , thyroid disease (Burney et al. 1999) , and Addison's disease (Lovas et al. 2002) .
Other questionnaires
Other questionnaires were also completed in these studies including the General Well-being Index 2 (Hunt & McKenna 1992) , the Well-being Questionnaire (Bradley 1994) , and a new hormone deficiency-specific individualised QoL questionnaire (HDQoL) (Bradley 1999 
I. The cross-sectional survey of GH-treated and non-GH-treated adults with GHD
Recruitment procedures
All participating patients had been diagnosed with GHD and received GHreplacement therapy for at least 6 months immediately prior to the study or had not received GH treatment in the previous 6 months; were aged between 18-70 years; had received appropriate adrenal, thyroid and gonadal hormone replacement therapy, as required by their hormonal condition, for at least 12 months prior to the study. Patients might have adult onset of GHD (AOGHD) or childhood onset (COGHD). Exclusion criteria were diabetes mellitus, active malignancy or pregnancy. The patients were to be severely GH deficient as determined by an Insulin Tolerance Test (ITT) or Pituitary Function Test in which insulin reduced blood glucose to ≤ 2.5 mmol/ L with peak GH concentration ≤ 10 mU/ L. However, there were no ITT results available for 21 patients because an ITT was too dangerous, an ITT had never been performed or because the laboratory test results were missing from the patient notes. In 18 of these 21 cases the assumption was made that because the patients were already receiving GH treatment, were about to be given GH treatment, or had received it in the past as adults, then the severity of the deficiency had been established, and that they could be included in this study. In 3 cases in the non-GHtreated group, clinicians were consulted about the patient's suitability for inclusion. Some patients were approached in a mailshot enclosing the questionnaires, others at weekly clinics.
Statistical analyses
Normality issues: Normality of distributions was investigated through standardised z (skew) values (Tabachnik & Fidell 1983) . Item data were not transformed to normality, thereby sacrificing some of the accuracy of factor analyses for the convenience of having interpretability of original units. The assumption was made that if reliability were high, the factor analysis robust, and the number of respondents sufficiently high, then a degree of non-normality was acceptable. In sub-group analyses, Mann-Whitney tests were performed on skewed variables, and t-tests on normal data. Internal consistency reliability: Cronbach's alpha coefficients (Cronbach 1951) were determined, with acceptable alphas ranging from 0.7 (Todd & Bradley 1994) to 0.95. Acceptable item-total correlations were > 0.2 (Kline 1993) . Factor structure was explored with Principal Components Analysis. Forced one-factor solutions were obtained for individual subscales to confirm the validity of calculating subscale totals. Salient loadings were taken as ≥ 0.4, higher than the recommended minimum 0.3 (Kline 1994) , erring on the side of caution in an effort to reduce the risk of spurious loadings that owed their origin to non-normality of item distributions. Construct validity was sought in some expected sub-group differences (GH-treated patients having generally better health status than non-GH treated patients, and men better than women). Health status was expected to improve with increasing duration of treatment and correlations were undertaken (for GH-treated patients). 'Familywise' error in multiple tests: The Holm's sequential Bonferroni procedure for multiple tests, cited (Green et al. 1997) , was adopted. A minimum significance value of 0.006 was required if 8 similar statistical tests were performed on the 8 subscales of the SF-36 and 0.008 for the 6-subscale NHP.
Analysis was conducted using SPSS for Windows (Release 7.5).
Results
The patient sample
Of 219 questionnaires distributed, 163 were returned (74.4% response rate), but 6 patients did not meet all inclusion criteria (e.g. were found to have diabetes mellitus), leaving 157 data sets for analysis. Fifty-six people either declined to participate or did not respond (23.5% GH-treated and 29.8% non-GH-treated patients).
Ninety-one GH-treated and 66 non-GH-treated patients participated. T-tests showed no significant between-treatment-group differences in Body Mass Index (BMI) or height (Table 1) ; Chi-Square tests showed no differences in numbers of men but the difference in numbers of GH-treated women (51) and non-GH-treated women (33) was significant. The mean age of GH-treated patients (47.1 years) was significantly younger than non-GH-treated patients (51.3 years). There were significantly more people with COGHD in the GH-treated group (21) than the non-GH-treated group (9).
( Table 1 here) Questionnaire completion rates were high: 98.5% (NHP) and 99.1% (SF-36) indicating high acceptability to respondents. Non-normality, (distributions skewed towards good health status), was found in a much greater proportion of NHP items (36/38) than SF-36 items (20/36). Indeed 31/38 dichotomous NHP items had ≥ 75% 'No' responses, indicating good health, and 23.7% of respondents scored 'No' on all 38 NHP items. The highest levels of dysfunction in the whole patient sample, found by the NHP, were for Energy (mean 34.28 ± 39.48, N = 153) and Sleep (21.34 ± 30.65, N = 153) . The SF-36 found highest dysfunction in Vitality (mean 49.59 ± 23.8) and General Health (56.0 ± 25.04). However, when compared with the results for the UK general population (Garratt et al. 1993) , the patient sample as a whole was found to have significantly worse perceived functioning in SF-36 subscales of General Health, Pain, Social Functioning, Roles Emotional and Physical, and Vitality (Table  2) . These results were similar to those found by other researchers when comparing healthy controls and patients with GHD e.g. in the Belgian population (Hakkaart-van Roijen et al. 1998 ).
( Table 2 here)
Reliability Analyses
NHP: All subscale alpha coefficients were acceptable (range: 0.74 to 0.89) and corrected item-total correlations within subscales satisfactory (range: 0.22 to 0.62). Reliability analysis of the whole NHP scale found a high Cronbach's alpha (0.92) but also indicated the unacceptability of the NHP Total score occasionally reported in the literature, as corrected item-total correlations for two items failed to reach the 0.2 criterion. SF-36: All subscale alphas were high for short scales of from 2 to 10 items (range: 0.78 to 0.94) and corrected item-total correlations within subscales were satisfactory (range: 0.43 to 0.89).
Factor analysis
NHP: Forced 1-factor analyses of the individual subscales found satisfactory loadings ≥ 0.4 for all except one Physical Mobility item which loaded at 0.321. A forced 1-factor analysis of the whole scale found 10/38 items loading at < 0.4, again indicating the invalidity of calculating an overall NHP Total Score. SF-36: Forced 1-factor analyses of subscales found all loadings satisfactory (≥ 0.57).
With the exception of NHP Physical Mobility, analyses supported the calculation of NHP and SF-36 subscale scores for adults with GHD.
Subgroup differences
GH-treatment group differences NHP: There were no significant differences on Mann-Whitney tests between the treatment groups (p values in range 0.16 to 0.99), though trends were in the expected direction of those receiving GH treatment having better health status than non-GH-treated patients on all subscales except Social Isolation. SF-36: T-tests were performed on all SF-36 subscales but the skewed Physical and Social Functioning subscales, for which Mann-Whitney tests were conducted. There were no significant between-treatment-group differences: p values in range 0.09 (Mental Health) to 0.83 (Role-Emotional). GH-treated patients had slightly better functioning than non-GH-treated patients in all subscales but Bodily Pain, Mental Health and Physical Functioning. A further analysis, excluding the 21 patients who did not meet the initial inclusion criteria (no ITT test result available), did not find any significant between-treatment-group differences. 
Correlations with duration of GH treatment in GH-treated patients
Age of onset of GHD
Neither questionnaire found significant differences in health status between those with AO or COGHD once Bonferroni corrections had been applied (full results not supplied).
Sex differences
Men had significantly better NHP Physical Mobility and significantly better health status in all SF-36 subscales but Mental Health compared with women (Table 3) . These are similar to results for the UK general population (Brazier et al. 1992 ). (Table 3 here) II. The randomised placebo-controlled trial of withdrawal of GH treatment from GH-treated adults.
Study Design
Patients were allocated to placebo or continued treatment with GH in a randomised, double-blind, placebo-controlled, parallel-groups study, in which patients selfadministered either GH (0.125 to 0.25 IU/ kg body weight/ week) or placebo for a period of 3 months. Lilly Industries Ltd supplied the vials of GH (Humatrope) which were indistinguishable from placebo. IGF-I was measured by double-antibody radioimmunoassay after acid/ ethanol extraction, using a commercially available reagent pack (Amersham, Arlington Hts., III., within-assay c.v. < 5%). Questionnaires were given at baseline and end-point, 3 months later. All patients were attending the Endocrine Clinic of St Thomas' Hospital, London.
Recruitment procedures
Inclusion and exclusion criteria were similar to those in the cross-sectional study above except that all participating patients had received GH-replacement therapy for at least six months immediately prior to the study; were aged between 22-70 years; were taking adequate contraception, if women of childbearing age and potential. All patients had endogenous GH levels of ≤ 7.7 mU/ L at blood glucose ≤ 2.0 mmol/ L on provocative testing. Additional exclusion criteria were: clinically significant pulmonary, cardio-thoracic, renal or neuromuscular disease; clinically apparent chromosomal or genetic malformation syndromes; a history of alcohol or drug abuse; were unlikely to comply with the protocol; were taking oral and parenteral steroids, other than in replacement doses, which were likely to suppress the action of GH. Prospective participants were approached personally by clinicians.
Additional measures
Interviews were also conducted, results for which have been reported (McMillan 2001) . The number of serious negative life events and difficulties occurring in the 12 months prior to this study was assessed in the interviews using a short checklist [Life events and difficulties screening checklist] 3 modified from a screening checklist for stressful life events and chronic difficulties (Costello & Devins 1998) .
Hypotheses
When adults with GHD are given GH treatment, improvements in health status have been reported. There was general clinical expectation of deterioration in physiological /metabolic factors within the 3-month study period and that this might be accompanied by reduced health status (Sönksen et al. 1991) . It was therefore hypothesised that after 3 months' withdrawal of GH the Placebo group would exhibit, relative to baseline, decreased Energy, Emotional Functioning, Physical Mobility, Sleep and increased Social Isolation (higher scores on NHP); and decreased General Health, Mental Health, Physical Functioning, Social Functioning, and Vitality (reduced scores on SF-36) but GH-treated patients would show little change.
Statistical analyses
T-tests or Mann-Whitney tests were conducted on the differences between the treatment-group change scores over the withdrawal period. Bonferroni corrections were not applied to reduce the chance of Type II errors in a study with small sample size, and as it was unlikely that a significant result that had been predicted would be obtained by chance. The required significance level was set at < 0.05.
Results
The patient sample
Only 66 of the 144 adults with GHD being treated with GH at St Thomas' Hospital fulfilled the stringent inclusion criteria and were approached. However, 62% declined to participate, the majority because they were satisfied with their current treatmentnot wishing to risk withdrawal, with expected return of undesirable symptoms of GHD. Twenty-two patients were finally recruited into the study, but one patient withdrew from psychological aspects of the study just prior to baseline, and another (Placebo group), withdrew suddenly and prematurely from the study, about 2 weeks prior to end-point, owing to adverse symptoms. There was no significant difference in the number of men (23) and women (18) who declined to participate in the study, or in the age of people who refused and people who participated. The study sample was therefore representative of the patient pool in terms of age and sex. 
Biochemical changes
Three months after baseline the serum total IGF-I of placebo-treated patients fell from normal, age-related levels (mean 26.6 ± 3.8 nmol/ L) to levels indicative of severe GHD (11.6 ± 1.9 nmol/ L) (p < 0.001). Only a small, non-significant decrease was noted in GH-treated patients.
One patient in the GH-treatment group reported several adverse symptoms over the course of the withdrawal period. A large drop (-20.2 nmol/L or 39.3%) in his IGF-I levels were noted over the study, well outside the mean change of -1.74 ± 10.68 for the GH-treatment group and more than the mean change of -15.02 ± 12.38 in IGF-I levels for the Placebo group. However, his IGF-I level at end-point was in the normal range. After the study codes had been broken, the patient was asked if there were any reasons for this and he claimed that the injection pen may have malfunctioned. It is also possible that he did not fully adhere to the injection regimen, as he had a history of non-adherence. Analyses were therefore undertaken excluding the data of this anomalous case.
Questionnaire data
NHP: no significant between-group differences in change scores were found in Mann-Whitney tests. SF-36: As expected, a significant between-group difference in change was found in SF-36 General Health [t(17) = 2.76, p = 0.013, 2-tailed] with scores of placebo-treated patients dropping from 63.5 ± 19.6 at baseline to 57.0 ± 23.2, but scores of GH-treated patients increasing from 62.8 ± 23.9 to 66.1 ± 25.2, and for SF-36 Mental Health [t(17) = 2.41, p = 0.027, 2-tailed] with scores of placebotreated patients dropping from 75.0 ± 15.9 at baseline to 69.5 ± 21.0, but scores of GH-treated patients increasing from 77.5 ± 20.1 to 84.5 ± 7.2. Patients withdrawn from GH reported reduced general health and mental health at end-point. (Table 5 ).
Analysis of the single health transition item showed that, by end-point, 4 of the 12 placebo-treated patients (33.3%) considered their health worse than one year before, but only one patient in the GH-treated group (the outlier whose IGF-I levels dropped considerably). (Table 5 here)
Discussion
The NHP has been one of the most frequently used questionnaires in research into adult GHD, yet it is known to have certain disadvantages. It is designed for more severe illness and therefore has highly skewed distributions in relatively healthy populations, with reduced sensitivity to between-group differences, reduced sensitivity to change (Bowling 1991 ) and inability to detect low levels of morbidity. Such criticisms were confirmed in the present studies. For all individual NHP items the majority of respondents in the cross-sectional survey answered 'No', that they perceived no health problem in that area, indeed almost a quarter of respondents reported no health problem in any of the 38 items. The wider range of SF-36 response options means that more information is available about different degrees of impairment, thus the SF-36 had greater discriminatory power. Responses to individual items of the SF-36 showed that most respondents in the cross-sectional survey were not limited at all in moderate activities and only felt limited in vigorous activities such as climbing several flights of stairs. However, patients had significantly worse health status for most SF-36 subscales than the UK general population.
Both NHP and SF-36 have good acceptability to adults with GHD (as indicated by high completion rates), and good internal consistency reliability. However, reliability and factor analyses of the whole 38-item NHP scale confirmed the inadvisability of calculating a NHP Total score, as occasionally reported in the literature.
In the cross-sectional study the SF-36 showed more sensitivity to expected sex differences than the NHP. Women had significantly worse health status than men on all SF-36 subscales but Mental Health, but on only one NHP subscale, (Physical Mobility). In the general population, women's health status is worse than men's, (Brazier et al. 1992; Hunt & McKenna 1989) , and in adult GHD women have also tended to exhibit worse health status (NHP) than men. No significant differences in health status were found between patients with CO and AOGHD although these are different clinical entities (Attanasio et al. 1997) : CO patients are more underdeveloped physically and AO patients have greater lipid abnormalities. There have been few studies comparing health status in the two groups. Whilst one study found no difference in health-related QoL (Abs et al. 1999) another study found significantly reduced physical mobility and energy in AO than COGHD (Attanasio et al. 1997) .
Whilst the SF-36 Mental Health and Vitality subscales showed correlations indicative of improving health status for GH-treated patients with longer periods of GH treatment, neither questionnaire found significant GH treatment-group differences. It could be that neither questionnaire was sensitive to treatment group differences, or that there were no real differences in perceived health status between the 2 groups. It may be that people prescribed GH treatment present with more serious symptoms of mental and physical ill-health but GH treatment improves their health status to a level little different from people with GHD who are untreated perhaps because they are managing quite well without it. The results appear to indicate that an appropriate subgroup of patients were prescribed GH treatment -perhaps the result of a combination of clinical acumen and patient pressure from those adversely affected by GHD. In the study as a whole, however, significant findings were limited to a few selected comparisons (e.g. sex differences and differences from the healthy general population). Insufficient data were available to conduct further analyses of betweengroup differences.
Recruitment difficulties for the GH-withdrawal study indicated that the majority of patients did not want to risk withdrawal from GH-treatment, and the anticipated negative effect that it would have on their lives. The small pool of patients suitable for inclusion in the GH-withdrawal study, combined with a high refusal rate, resulted in a small sample of 21 patients, and low power of analysis. One placebo-treated patient withdrew from the study just prior to end-point owing to adverse symptoms. The possible non-adherence to the study protocol of one GH-treated patient further reduced the data available for analysis. Whilst it might have been more logical and less problematic to investigate the questionnaires' sensitivity to change with GH replacement, for which there would be no recruitment problems, there was no opportunity for such a study at the time.
In the GH-withdrawal study, where health status of placebo-treated patients was expected to worsen, the NHP found no significant between-treatment-group differences. The SF-36, on the other hand, had two significant findings in the expected direction (of worsening health in the Placebo group) in the General Health and Mental Health subscales. In a study such as the GH-withdrawal study, where power was low, the NHP was not sufficiently sensitive to change. It is possible that some of the negative findings for the benefits of GH treatment in the literature, might have been the result of the lack of sensitivity of the questionnaire chosen to measure change, the NHP.
The relationship between hormonal abnormalities and psychological consequences is complex (Fava et al. 1993) . These studies did not cover the effects of patients' other hormone deficiencies or endocrine disease (if any). Patients with diabetes were excluded from the studies, and only those patients who were being treated with appropriate adrenal, thyroid and gonadal hormone replacement therapy were included. However, there is some evidence that some patients still exhibit psychological symptoms (particularly depression or anxiety) even if their hormone levels have been normalised with therapy (Lovas et al. 2002; O'Malley et al. 2000; Sonino & Fava 2001) . Full details of other hormone deficiencies were not recorded in the cross-sectional study, although are available for the longitudinal study. It is not possible to say whether any psychological distress was due to another endocrine condition, but this should be borne in mind when interpreting results.
Conclusion
In conclusion, the present studies have shown that the SF-36 is a better measure than the NHP of health status of people with GHD, owing to its greater discriminatory power with ability to detect lesser degrees of disability. It also has superior sensitivity to some sub-group differences and superior sensitivity to change than the NHP. The SF-36 is highly acceptable to respondents, and has very good internal consistency reliability. The SF-36 is recommended to measure the health status of adults with GHD. Subscale range 0-100, with higher score indicating better health status/ functioning. **Means for a healthy UK general population, from Garratt et al. (1993) . 
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